Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ice × 1 year × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

pembrolizumab 193 Nivolumab 108 Cyclophosphamide 106 Carboplatin 88 venetoclax 69 Gemcitabine 68 Bevacizumab 68 fludarabine 63 Dexamethasone 63 Specimen Handling 60 Injections 59 Magnetic Resonance Spectroscopy 57 Paclitaxel 56 atezolizumab 54 Biopsy 54 Cisplatin 47 Ipilimumab 46 Temozolomide 42 Rituximab 42 Pemetrexed 41 Docetaxel 40 Azacitidine 39 Oxaliplatin 38 Radiotherapy 37 Cetuximab 36 Lenalidomide 35 Fluorouracil 35 Prednisone 34 Irinotecan 34 Cytarabine 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡